Type: Product
Name: Aloxi
First reported Apr 11 2014 - Updated Apr 11 2014 - 1 reports

AtheroNova appoints new COO

AtheroNova Inc., a biotechnology company, has appointed Randolph Johnson as its new COO. "We are pleased to announce that Dr Johnson has joined AtheroNova's management team, bringing his talents and leadership to AtheroNova's efforts to develop our platform ... [Published - Apr 11 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 1 reports

AtheroNova Appoints Dr. Randolph M. Johnson as Chief Operating Officer

(GLOBE NEWSWIRE) -- AtheroNova Inc. (OTCBB:AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announced that Randolph M. Johnson, Ph.D. has ... [Published - Apr 08 2014]
First reported Dec 23 2013 - Updated Dec 23 2013 - 1 reports

Helsinn, Mundipharma ink distribution and license pact for netupitant-palonosetron FDC

Helsinn, a Swiss-based privately owned pharmaceutical group, and Mundipharma have signed a new, exclusive license and distribution agreement, covering China, Hong Kong and Macao, for netupitantpalonosetron fixed dose combination (NEPA), a Helsinn product ... [Published PharmaBiz - Dec 23 2013]


"Dr Johnson is a seasoned pharmaceutical executive with strength in drug discovery, R&D and in the operational aspects of running companies in this industry. As we accelerate our research into synthetic and analog versions of our compounds for enhanced efficiency as well as expanded intellectual property claims, Dr Johnson's expertise will be invaluable. Everyone on the AtheroNova team is looking forward to Dr Johnson's contributions to the Company's first-in-class compounds for atherosclerosis regression and lipid modulation technology."
"We are committed to pursuing new and innovative treatments that markedly improve the quality of patients’ lives in every market we are present. By launching NEPA in China, we hope to provide healthcare professionals access to a treatment option for cancer patients that optimizes prevention of chemotherapy-induced conditions. Our collaboration with Helsinn Group marks a new milestone, given their proven track record of innovation in cancer supportive care,” said Raman Singh, regional managing director of Mundipharma Asia, Latin America, Middle East and North Africa."

More Content

All (3) | News (3) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
AtheroNova appoints new COO [Published - Apr 11 2014]
AtheroNova Appoints Dr. Randolph M. Johnson as ... [Published - Apr 08 2014]
Helsinn, Mundipharma ink distribution and licen... [Published PharmaBiz - Dec 23 2013]
Contact Us

Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.